LACI-3 developments, news and latest updates for current study participants Participant factsheets and information LACI-3 Participant Factsheets: Standard of Care & Control Group within LACI-3 Document LACI-3 Standard of Care (165.82 KB / PDF) Document Who receives standard care (92.56 KB / PDF) Investigational Medicinal Product (IMP) ManagementAn IMP in a clinical trial is the specific active drug, biological product, or placebo being tested or used as a reference comparison. Document below gives information to participants as to how to manage IMPs (cilostazol and/or isosorbide mononitrate) on the trial. Document Investigational Medicinal Product (61.72 KB / PDF) Participant Newsletters Newsletters 2026 Document LACI-3 Participant Newsletter April 2026 (3.78 MB / PDF) Newsletters 2025 Document LACI-3 Participant Newsletter November 2025 (1.01 MB / PDF) This article was published on Tuesday 18 November 2025
